Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate.

Fleischmann, Roy; Haraoui, Boulos; Buch, Maya H; Gold, David; Sawyerr, Gosford; Shi, Harry; Diehl, Annette; Lee, Kristen

Fleischmann, Roy; Haraoui, Boulos; Buch, Maya H; Gold, David; Sawyerr, Gosford; Shi, Harry; Diehl, Annette; Lee, Kristen.

Afiliación

Fleischmann R; Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, USA.
Haraoui B; Institut de Rhumatologie de Montréal, Montreal, QC, Canada.
Buch MH; Centre for Musculoskeletal Research, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester, UK.
Gold D; Pfizer Canada ULC, Kirkland, QC, Canada.
Sawyerr G; Pfizer Inc, New York, NY, USA.
Shi H; Pfizer Inc, 500 Arcola Rd, Collegeville, PA, 19426, USA.
Diehl A; Pfizer Inc, 500 Arcola Rd, Collegeville, PA, 19426, USA.
Lee K; Pfizer Inc, 500 Arcola Rd, Collegeville, PA, 19426, USA. kristen.lee@pfizer.com.

Rheumatol Ther ; 10(2): 375-386, 2023 Apr.

Article en En | MEDLINE | ID: mdl-36534208

Palabras clave

Inflammation; Methotrexate; Rheumatoid arthritis; Therapeutics

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Rheumatol Ther Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google